Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA and American Society of Health-System Pharmacists.
- Pemetrexed disodium injection: Multiple presentations of pemetrexed disodium injection, including 100 milligram and 500 milligram vials, have been discontinued. The drug is used in combination with other therapies for non-small cell lung cancer and mesothelioma.
- Adalimumab biosimilars: Adalimumab-afzb and Abrilada, both biosimilars to Humira, have been discontinued. These injections are used to treat rheumatoid arthritis, Crohn’s disease and other autoimmune conditions.
- Hydrocortisone sodium succinate injection: Hydrocortisone sodium succinate 100 milligram vials are in limited supply due to increased demand. The corticosteroid is used for allergic reactions, adrenal insufficiency and inflammation.
- Paricalcitol capsules: The 1, 2 and 4 microgram oral capsule strengths of paricalcitol from Bionpharma and Time-Cap Labs are in shortage. Bionpharma’s products are on allocation and Time-Cap’s are on backo=rder with no estimated resupply date. The FDA also listed the 1 and 2 microgram formulations as discontinued.
- Cobicistat tablets: Cobicistat 150 milligram tablets, marketed as Tybost, are being discontinued for business reasons. Supply is expected to continue through February 2026. Cobicistat is used as a pharmacokinetic enhancer in HIV treatment.
- Omeprazole delayed-release capsules: Omeprazole capsules have been discontinued. The proton pump inhibitor is commonly used to treat gastroesophageal reflux disease and other acid-related gastrointestinal conditions.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
